Log on / register
Feedback | Support | My details
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.
Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD
BMC Cancer 2007, 7:134
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

PubMed Central articles that cite the above article:

1.
Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort.
Giltnane JM, Moeder CB, Camp RL, Rimm DL
Cancer 2009 Jun 1, 115:2400-9
 [PubMed Central] [PubMed] [Related articles]
2.
Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
Spearman AD, Sweet K, Zhou XP, McLennan J, Couch FJ, Toland AE
J Clin Oncol 2008 Nov 20, 26:5393-400
 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 5 articles in BioMed Central


You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.